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OBJECTIVES We sought to evaluate cardiac troponin I (cTnI) for predicting early clinical outcomes and the
efficacy of enoxaparin among patients with non–ST segment elevation acute coronary
syndrome (ACS) and negative creatine kinase, MB fraction (CK-MB) levels.
BACKGROUND Cardiac TnI identifies patients with unstable angina who are at higher risk of death or
myocardial infarction (MI) by 30 days. The utility of cTnI for predicting very early clinical
events, including recurrent ischemia, and the efficacy of enoxaparin are not yet established.
METHODS At baseline and 12 h to 24 h after enrollment in the Thrombolysis in Myocardial Infarction
(TIMI)-11B trial, samples were collected for cTnI determination.
RESULTS Among 359 patients with negative serial CK-MB values, 50.1% had a cTnI result $0.1 ng/ml
within the first 24 h. Patients with elevated cTnI were at higher risk of death or MI at 48 h
(3.9 vs. 0%, p 5 0.01) and 14 days (13.9 vs. 2.2%, p , 0.0001). Elevated cTnI also correlated
with higher risk of recurrent ischemia requiring urgent revascularization by 48 h (10.0 vs.
1.7%, p 5 0.001) and 14 days (20.6 vs. 5.6%, p # 0.0001). Enoxaparin had a greater benefit
among patients with elevated vs. normal cTnI (p 5 0.03), achieving a 47% reduction in the
risk of death, MI or urgent revascularization by 14 days in cTnI-positive patients (p 5 0.007).
CONCLUSIONS Elevation of cTnI among patients with non–ST segment elevation ACS and negative levels
of CK-MB identifies those at higher risk for very early adverse outcomes, including severe
recurrent ischemia. Treatment with enoxaparin reduces the risk associated with elevated
cTnI. (J Am Coll Cardiol 2000;36:1812–7) © 2000 by the American College of Cardiology
Patients with unstable angina are heterogeneous with re-
spect to prognosis and present a particular challenge for
early risk assessment and triage (1,2), compared with pa-
tients with elevated levels of creatine kinase, MB fraction
(CK-MB), who may be recognized as being at higher risk
(3). Cardiac-specific troponin I (cTnI) is a highly sensitive
and specific marker of myocardial necrosis (4) that has
demonstrated prognostic utility among the substantial pro-
portion of patients with non–ST segment elevation acute
coronary syndrome (ACS) who have no elevation of
CK-MB (5–8). We have shown previously that elevation of
cTnI $0.4 ng/ml at the time of presentation identifies
patients with ischemic symptoms and normal CK-MB who
are at higher risk of death by 42 days (5). Other clinical
studies have demonstrated that elevated levels of cTnI are
associated with a higher incidence of death or myocardial
infarction (MI) by 30 days among patients with chest pain
suspicious for angina (9) and documented unstable coronary
disease (6–8). However, data evaluating the relation be-
tween cTnI and the occurrence of refractory angina, as well
as the need for revascularization, have been inconclusive
(6,7). Furthermore, published data regarding the prognostic
utility of cTnI for predicting the risk of clinical events at
very early time points (e.g., 48 h) in patients with unstable
angina are limited. Finally, current generation cTnI assays
offer greater analytic sensitivity than previous versions and
have created the need for clinical evaluation of lower cTnI
thresholds for risk assessment in ACS (10).
Given increasing economic pressure to constrain the
duration of inpatient management and to target more
expensive and aggressive therapies, the ability to identify at
presentation those patients with ischemic symptoms and
negative CK-MB who are at higher risk for early adverse
outcomes has taken on particular clinical importance. In
addition, data documenting an association between eleva-
tion of cardiac troponin T and enhanced efficacy of specific
medical therapies (11–14) have demonstrated the potential
for the cardiac troponins in guiding early management
decisions. Thus, we have evaluated cTnI at a threshold of
0.1 ng/ml, using a current generation assay (Dimension
RxL, Dade Behring, Newark, Delaware), for the purpose of
predicting early adverse cardiac events, including recurrent
ischemia necessitating urgent revascularization by 48 h and
14 days, among patients with unstable angina enrolled in
Thrombolysis in Myocardial Infarction (TIMI)-11B Trial.
In addition, we tested for any interaction between cTnI
results and the efficacy of enoxaparin over unfractionated
heparin (UFH) therapy.
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METHODS
Patients. Men and women with unstable angina enrolled at
any of 63 North or South American centers participating in
the biomarker protocol of TIMI-11B were eligible for this
substudy. The diagnosis of the presenting ischemic syn-
drome was made by the local investigator on the basis of
World Health Organization criteria for MI, using local
serial measurements of CK or CK-MB as defined in the
TIMI-11B protocol (15) and collected on the Initial Hos-
pitalization Case Report Form. Patients presenting with an
ischemic syndrome without acute MI were diagnosed with
unstable angina.
TIMI-11B was a randomized, double-blind, parallel
group trial of the low molecular weight heparin, enoxaparin,
as compared with UFH, for the treatment of high risk
patients presenting with non–ST segment elevation ACS.
The trial design and inclusion and exclusion criteria of
TIMI-11B have been published previously (15). Partici-
pants were required to have symptoms at rest within the
previous 24 h and evidence of ischemic heart disease (15).
Exclusion criteria included plans for revascularization in the
first 24 h, regardless of the initial response to medical
therapy, coronary artery bypass graft surgery (CABG)
within the previous two months or percutaneous translumi-
nal coronary angioplasty (PTCA) within six months and
renal insufficiency (serum creatinine .2.0 mg/dl). The
TIMI-11B protocol, including the biomarker substudy, was
approved by the institutional Committee on Human Re-
search at each of the participating centers.
During the acute phase of TIMI-11B, patients were
treated with either intravenous UFH (n 5 190) or weight-
adjusted dosing of subcutaneous enoxaparin (n 5 169). The
median duration of treatment with intravenous UFH and
acute-phase subcutaneous enoxaparin in the substudy group
was 3.0 and 3.5 days, respectively. Patients eligible for the
chronic-term phase (e.g., no bleeding or CABG) were then
administered fixed-dose subcutaneous enoxaparin or pla-
cebo for an additional 35 days (59% of patients in the
enoxaparin group and 52% in the UFH/placebo group),
starting at the time of discharge or day 8, whichever
occurred first.
Blood sampling and measurement of serum markers.
The serum marker protocol specified that on enrollment and
12 h to 24 h later, venous blood samples be drawn and
serum stored at 220°C or colder at the enrolling site until
shipped to the Core Laboratory at Children’s Hospital
Medical Center (Boston, Massachusetts), where they were
stored at 280°C until analyzed.
Cardiac TnI results were determined in the Chemistry
Laboratory at Brigham and Women’s Hospital (Boston,
Massachusetts) on thawed sera using the Dimension RxL
cTnI assay (Dade Behring). All operators had no knowledge
of patient treatment or clinical outcomes. The day-to-day
precision of this assay in the Brigham and Women’s
Hospital laboratory, at cTnI concentrations of 0.57 ng/ml,
2.58 ng/ml and 12.22 ng/ml, is reflected by coefficients of
variation of 8.8%, 3.1% and 1.5%, respectively. The minimal
detectable concentration is 0.04 ng/ml. The 97.5 percentile
for 197 healthy blood donors tested in our laboratory was
determined to be 0.1 ng/ml. In its “Standards of Laboratory
Practice: Recommendations for the Use of Cardiac Mark-
ers” the National Academy of Clinical Biochemistry has
recommended that the low abnormal decision limit for
cardiac troponins in ACS be guided by the 97.5 percentile
among normal control subjects (16). Consistent with this
recommendation and clinical experience in our laboratory,
we used a level of 0.1 ng/ml as the cTnI threshold for
analyses in this substudy.
Definitions. The clinical end point of MI in TIMI-11B
was restricted to a new MI occurring after the qualifying
ischemic event and included either new diagnostic Q waves
or left bundle branch block not present on the enrollment
electrocardiogram (ECG) or enzyme evidence of a new
infarction (15). Elevation of CK-MB above the upper limit
of normal (ULN) and at least 50% over the previous value
or, if the CK-MB value was unavailable, elevation of total
CK above two times the ULN and $25% of the previous
value was necessary to meet enzymatic criteria for a new MI.
For patients within 24 h of PTCA or CABG, total CK and
CK-MB values were required to be $50% of the previous
value and three and five times the ULN, respectively (15).
Participants were determined to have recurrent ischemia
requiring urgent revascularization if they had either recur-
rent angina prompting the performance of coronary revas-
cularization during the same hospital stay or an episode of
unstable angina after discharge, resulting in repeat hospital
admission and coronary intervention. All clinical end points
in TIMI-11B, including recurrent ischemia requiring ur-
gent revascularization, were adjudicated by an independent
Clinical Endpoints Committee, which had no knowledge of
treatment assignment, incorporating a detailed review of
relevant ECGs, serum marker data, angiographic findings
and a narrative summary.
Statistical analysis. Statistical comparison of baseline
characteristics and clinical outcomes were performed using
the chi-square or Fisher exact test for dichotomous variables
and either the Wilcoxon rank-sum or two-sample t test for
Abbreviations and Acronyms
ACS 5 acute coronary syndrome
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
CK-
MB 5 creatine kinase, MB fraction
cTnI 5 cardiac troponin I
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary
angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction
UFH 5 unfractionated heparin
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continuous variables. Multivariate analyses were performed
using a logistic regression model incorporating recognized
cardiovascular risk factors (age, gender, history of coronary
artery disease, diabetes, hypertension, tobacco use, ST
segment deviation and presence of congestive heart failure at
presentation). Testing for a significant interaction between
categoric cTnI results and treatment arm was performed
using the Breslow-Day test for homogeneity. Data analyses
were performed using SAS statistical software (version 6.12,
SAS Institute, Cary, North Carolina). All statistical com-
parisons were two-tailed, and p , 0.05 was considered to
indicate statistical significance.
RESULTS
Baseline characteristics. This substudy of TIMI-11B in-
cluded 359 patients with unstable coronary disease and
negative serial CK-MB measurements who had serum
samples obtained at baseline or 12 h to 24 h after enroll-
ment, or both, available for determination of cTnI values in
our laboratory. Demographic characteristics of patients
eligible for this serum marker substudy showed higher rates
of hypertension, previous angina and CABG, but were
otherwise representative of those in the overall trial (Table
1), with a profile typical of patients presenting with severe
unstable ischemic heart disease, including high rates of
previous coronary artery disease (46%) and ST segment
changes on presentation (81%). Patients in the substudy
with a positive cTnI value ($0.1 ng/ml) were more likely to
be male and were slightly older (Table 1).
Cardiac TnI and clinical outcomes. Three hundred and
forty-one patients with negative CK-MB values had pre-
enrollment cTnI determinations, with 155 (45.5%) showing
elevated baseline cTnI levels. Of the 359 patients with
samples from either time point, 180 (50.1%) had a positive
cTnI result within the first 24 h after enrollment. There
were 13 deaths (3.6%) by 14 days in the substudy group.
Twenty-three patients (6.4%) had a MI after the qualifying
index event, and 47 (13.1%) had severe recurrent ischemia
requiring urgent revascularization.
Patients with an elevated cTnI value during the first 24 h
were at significantly increased risk for adverse clinical events
by as early as 48 h, as well as by 14 and 43 days (Table 2).
An elevated cTnI value identified patients at a 6% higher
absolute risk of death and a fourfold (95% confidence
interval [CI] 2.5 to 7.7) higher risk of death, nonfatal MI or
urgent revascularization (p , 0.0001) by two weeks after
presentation. Moreover, patients with an abnormal cTnI
value demonstrated a nearly sixfold higher risk of severe
ischemia requiring urgent revascularization by 48 h after
enrollment (p , 0.001), with a greater than 14% absolute
risk difference at both 14 and 43 days (p # 0.0001) (Table
2). Although utilization of the 12- to 24-h measurements
added to the strength of the prognostic relation, baseline
measurements alone were also highly predictive of each
component of the composite end point by 14 days (Fig. 1),
as well as severe recurrent ischemia requiring revasculariza-
tion by 48 h (10.3 vs. 1.6%, p 5 0.0005).
In a multivariate model including major clinical risk
factors (age, gender, diabetes, tobacco use, history of coro-
nary artery disease, hypertension), as well as the presence of
ST segment deviation (depression or transient elevation) on
the qualifying ECG, a cTnI level $0.1 ng/ml was an
Table 1. Baseline Characteristics
Characteristics
Group
TIMI-11B cTnI Substudy
All Patients
(n 5 3,910)
cTnI Substudy
(n 5 359)
cTnI Positive*
(n 5 180)
cTnI Negative
(n 5 179)
Age (years) 66.0 64.5 66.0 63.0‡
Male gender 64.8% 62.7% 68.9% 56.4%‡
Risk factors for CAD
Hypertension 49.7% 60.7%† 62.8% 58.7%
Current smoker 26.8% 24.8% 21.7% 27.9%
Hyperlipidemia 32.7% 36.8% 38.9% 34.6%
Diabetes mellitus 19.9% 23.7% 27.2% 20.1%
History of CAD
Angina 57.1% 65.2%† 63.9% 66.5%
Myocardial infarction 31.7% 35.1% 37.8% 32.4%
PTCA 11.6% 14.2% 11.7% 16.8%
CABG 13.4% 17.8%† 18.3% 17.3%
ECG changes
ST segment elevation 26.8% 28.1% 30.5% 25.7%
ST segment depression 55.0% 59.9% 62.2% 57.5%
T-wave inversion 42.1% 35.7%† 38.3% 32.9%
No ECG changes 17.2% 14.8% 12.2% 17.3%
*Considered positive if $0.1 ng/ml. †p , 0.05 as compared with entire TIMI-11B population. ‡p , 0.05 as compared with
substudy group with positive cTnI. Data, except for age, are expressed as the percentage of the total number in each subgroup.
CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery disease; cTnI 5 cardiac troponin I; ECG 5
electrocardiographic; PTCA 5 percutaneous transluminal coronary angioplasty; TIMI-11B 5 Thrombolysis in Myocardial
Infarction-11B Trial.
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independent predictor of adverse clinical outcomes at 14
days (Table 3). Furthermore, baseline elevation of cTnI was
independently associated with a higher risk of severe recur-
rent ischemia necessitating urgent revascularization at 48 h
(p 5 0.005) and 14 days (p 5 0.003).
Cardiac TnI and enoxaparin treatment. Consistent with
the superior efficacy of enoxaparin over UFH in patients in the
main TIMI-11B trial (15), patients in the cTnI substudy
treated with enoxaparin had fewer adverse clinical events
(death, MI or urgent revascularization) by 14 days (relative risk
0.65, 95% CI 0.40 to 0.97). Stratification of the substudy group
by cTnI results from 0 to 24 h revealed a greater relative benefit
of enoxaparin therapy among patients with an abnormal cTnI
value (Breslow-Day test, p 5 0.03, indicating heterogeneity of
the treatment effect of enoxaparin vs. UFH with respect to
death, MI or urgent revascularization). Patients with an ele-
vated cTnI value experienced a 17% absolute reduction in the
risk of severe recurrent ischemia prompting revascularization
and nearly half the risk of death, MI or urgent revascularization
by 14 days (Fig. 2).
DISCUSSION
In this substudy of patients with unstable coronary syn-
dromes and negative serial CK-MB measurements enrolled
in TIMI-11B, elevated levels of cTnI ($0.1 ng/ml) soon
after presentation were strongly associated with very early
adverse clinical outcomes, including a sixfold higher risk of
recurrent ischemia requiring urgent revascularization by as
early as 48 h after the initiation of study medication.
Notably, an abnormal cTnI value identified patients who
were at higher risk for each component of the composite
end point (death, MI and recurrent ischemia prompting
urgent revascularization) at 14 days. Consistent with previ-
ous observations, although elevated baseline levels of cTnI
were highly correlated with recurrent cardiac events, repeat
determination 12 h to 24 h after presentation added to the
prognostic capacity of the marker. Furthermore, cTnI of-
fered prognostic information independent of established
clinical risk markers, including age and ST segment devia-
tion on the presenting ECG, and identified higher risk
patients who demonstrated particular benefit from enoxapa-
rin versus UFH therapy.
Cardiac TnI and prognosis in unstable angina. A number
of previous studies have evaluated the prognostic capacity of
cTnI in patients with suspected ischemic syndromes but no
elevation of CK-MB. Among 948 patients with non–ST
segment elevation ACS and negative CK-MB enrolled in
TIMI-IIIB, elevation of baseline cTnI $0.4 ng/ml, as mea-
sured with an earlier generation assay (Stratus II, Dade
Behring), was associated with a threefold higher mortality risk
at six weeks (5). Galvani et al. (6) made similar observations
regarding the prognostic capacity of cTnI with respect to death
and nonfatal MI at 30 days and one year among 91 patients
Figure 1. Clinical outcomes at 14 days stratified by baseline cTnI results
(n 5 341). D/MI/UR 5 death, MI or urgent revascularization.
Table 3. Multivariate-Adjusted Risk Relation Between Elevated
Cardiac Troponin I and Adverse Outcomes at 14 Days
Outcome
Wald
Chi-Square
Multivariate Analysis
p Value
Adjusted OR
(95% CI)
Baseline cTnI positive
Death 5.8 0.02 10.9 (1.6–75)
Death or MI 9.4 0.002 5.1 (1.8–14)
Death, MI or UR 17.5 , 0.0001 4.0 (2.1—7.7)
Any cTnI positive
Death 5.7 0.02 16 (1.7–155)
Death or MI 9.1 0.002 5.5 (1.8–17)
Death, MI or UR 20.4 , 0.0001 4.7 (2.4–9.2)
“Any” cardiac troponin I (cTnI) refers to any positive result obtained in the first 24 h
after enrollment.
CI 5 confidence intervals; MI 5 myocardial infarction; OR 5 odds ratio; UR 5
urgent revascularization.
Table 2. Clinical Outcomes Stratified by Cardiac Troponin I Results
Clinical Outcomes (%)
48 Hours 14 Days 43 Days
Positive
(n 5 180)
Negative
(n 5 179) p Value
Positive
(n 5 180)
Negative
(n 5 179) p Value
Positive
(n 5 180)
Negative
(n 5 179) p Value
Death 0 0 NS 6.7 0.6 0.002 8.3 3.4 0.04
MI 3.9 0 0.01 11.1 1.7 , 0.001 13.3 2.2 0.0001
Death or nonfatal MI 3.9 0 0.01 13.9 2.2 , 0.0001 17.2 3.9 , 0.0001
Urgent revascularization 10.0 1.7 , 0.001 20.6 5.6 , 0.0001 21.7 7.3 0.0001
Composite end point 13.9 1.7 , 0.0001 31.7 7.3 , 0.0001 35.6 10.6 , 0.0001
“Positive” and “negative” refer to cardiac troponin I (cTnI) results obtained during the first 24 h after enrollment, with positive cTnI results $0.1 ng/ml. Composite end point
indicates death, myocardial infarction or urgent revascularization.
MI 5 myocardial infarction; NS 5 nonsignificant ($0.05).
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with Braunwald class IIIB unstable angina. Data from the
ThRombin Inhibition In Myocardial ischemia (TRIM) inves-
tigators (7) demonstrated that cTnI levels $2.0 ng/ml (Opus,
Behring Diagnostics) were associated with higher 30-day
mortality among 309 patients with unstable angina. A meta-
analysis including each of these studies showed a cumulative
odds ratio of 4.2 (95% CI 2.7 to 6.4) for death or MI over a
mean follow-up period of 42 days after presentation with
unstable angina and elevated cTnI (8).
Data from TIMI-11B— clinical implications. Our cur-
rent report expands on previous studies in several areas of
clinical importance. Although the predictive capacity of
cTnI with respect to death and MI at four to six weeks after
presentation with unstable angina is well documented (5–
8), data regarding earlier clinical outcomes are limited. In
addition, although several previous investigations have di-
rectly explored the relation between cTnI levels and the
incidence of recurrent ischemia or revascularization, or both,
the data from these studies have been inconclusive (6,7,17).
Our report addresses each of these areas that impact
decisions regarding the early management of patients with
non–ST segment elevation ACS and negative CK-MB
values, who might otherwise be considered at lower short-
term risk for poor outcomes. These data also suggest that
angiographic observations of an association between tropo-
nin elevation and thrombus burden/lesion complexity (18)
may have immediate clinical relevance with respect to the
patient’s risk of early recurrent ischemic events.
Cardiac TnI and therapeutic decision-making. Given
that economic and safety considerations are likely to pro-
hibit the uniform use of expensive pharmacologic and
invasive therapies, the identification of patients with
non–ST segment elevation ACS who will benefit most from
these interventions has become central to the care of this
group of patients. Our report suggests that cTnI levels
measured soon after presentation are useful in selecting
patients with negative CK-MB values who are at higher risk
for early adverse outcomes, including severe recurrent isch-
emia, and who might therefore be considered candidates for
more aggressive medical therapy or an early invasive inter-
vention. Our findings also offer evidence that treatment
with enoxaparin, a low molecular weight heparin with
demonstrated superiority over UFH (15), reduces the risk of
poor outcomes associated with an abnormal cTnI level. As
such, our data indicate that cTnI, like cardiac troponin T
(11,13), may be useful in targeting new antithrombin and
antiplatelet (12,14) therapies.
Study limitations. The TIMI-11B substudy enrolled a
high risk group of patients with non–ST segment elevation
ACS. One must maintain some caution in extrapolating our
data on patients with evidence of ischemic heart disease to
more heterogeneous populations with chest symptoms.
Furthermore, a number of factors contribute to analytic
variability between cTnI methods, as reflected in the diver-
sity of decision limits used in clinical laboratories and
reported in the literature (19–21). Thus, although our
results provide an evidenced-based guide for the clinical use
of a current generation assay (Dimension RxL), one should
be wary of generalizing the threshold used in this study to
other cTnI assays. Nevertheless, it is interesting to note that
in a diverse group of patients with chest pain, a bedside device
with a detection limit of 0.1 ng/ml (Spectral Diagnostics;
Toronto, Canada) reliably identified patients at higher risk for
cardiac death or nonfatal MI over a follow-up of 30 days (9).
Although during the period of this study, few centers
participating in TIMI-11B were measuring cardiac tro-
ponins in their local laboratories, we cannot exclude the
possibility that in few cases, local marker results might have
influenced the investigator’s decisions regarding revascular-
ization. However, the end point of severe recurrent ischemia
prompting urgent revascularization was carefully adjudi-
cated by an independent Clinical Events Committee and
required evidence that both an episode of recurrent ischemia
had occurred and the recurrent ischemia had prompted
revascularization. Furthermore, given that treatment alloca-
tion was blinded, there is no reason to expect systematic bias
in the interpretation of any local laboratory measurements
with respect to the treatment arm.
Conclusions. This cTnI substudy from TIMI-11B dem-
onstrates a consistent and significant increase in the risk of
early adverse cardiovascular outcomes associated with ab-
normal levels of cTnI among patients with non–ST segment
elevation ACS and negative values of CK-MB. The pre-
dictive capacity of cTnI is evident as early as 48 h after
presentation and is independent of multiple, well-described
clinical risk factors, including age and ST segment devia-
tion. Moreover, an elevated cTnI value identifies patients
who may derive particular benefit from enoxaparin therapy.
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Figure 2. Clinical outcomes at 14 days for patients treated with enoxaparin
versus UFH stratified by 0- to 24-h cTnI results. CI 5 confidence interval;
D/MI/UR 5 death, MI or urgent revascularization; RR 5 relative risk of
the outcome for patients treated with enoxaparin versus UFH.
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